ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Hypertension as an independent risk factor for severity and mortality in patients with COVID-19: a retrospective study

Chen, Jiankun; Liu, Yuntao; Qin, Jinying; Ruan, Chunyan; Zeng, Xianghui; Xu, Aiting; Yang, Rongyuan*; Li, Jiqiang*; Cai, Huayang*; Zhang, Zhongde广东省人民医院; 广州中医药大学
Postgraduate Medical Journal2022-7DOI: 10.1136/postgradmedj-2021-140674
16被引3阅读
引用收藏
分享

摘要

Purpose of the study Hypertension is one of the most common comorbidities in COVID-19 pneumonia. However, whether it is an independent factor on the severity and mortality of COVID-19 has not been studied. Study design In this study, 736 patients with a PCR-confirmed diagnosis of COVID-19 were included from 12 January 2020 to 25 March 2020. All patients were divided into two groups according to whether or not they were hypertensive. After propensity score matching (PSM) to remove the interference of mismatches in the baseline data, the clinical characteristics and outcomes of angiotensin II receptor blocker (ARB)/ACE inhibitors application were analysed. Results A total of 220 (29.9%) patients were hypertensive, and 516 (70.1%) patients were not hypertensive. PSM eliminated demographic and comorbidity differences between the two groups. Of all participants, 32 patients died (4.3% mortality), including 17 out of 220 in the hypertension group (7.7%) and 15 out of 516 in the non-hypertension group (2.9%). The incidence of intensive care unit (ICU) stay in the hypertension group (12.8%) was higher than in the non-hypertension group (5.3%) (p<0.05). Logistic regression analysis showed that hypertension was an independent risk factor for death, not other comorbidities. Kaplan-Meier analysis showed that mortality was higher in the hypertension group than in the non-hypertension group before and after PSM (p<0.05). There was no statistically significant difference in ICU therapy, mortality and hospitalisation time between hypertensive patients with or without ARBs/ACE inhibitors (p>0.05). Conclusion Hypertension was an independent risk factor for the severity and mortality of patients with COVID-19. ARBs/ACE inhibitors should not be discontinued in hypertensive patients with COVID-19.

学科与关键词

关键词
COVID-19hypertensiongeneral medicine
相关
加载中…
  • Hypertension in Patients Hospitalized with COVID-19 in Wuhan, China A Single-Center Retrospective Observational Study
    Zhang, Yuan; Sha, Tong; Wu, Feng; Hu, Hongbin; Chen, Zhongqing; Li, Haijun; Han, Jiafa; Song, Wenhong; Huang, Qiaobing*; Zeng, Zhenhua*International Heart Journal, 2021, 62(2): 337-343.被引 4
  • Association between hypertension and prognosis of patients with COVID-19: A systematic review and meta-analysis
    Qian, Zhe; Li, Zhuohong; Peng, Jie; Gao, Qiqing; Cai, Shaohang*; Xu, Xuwen*Clinical and Experimental Hypertension, 2022, 44(5): 451-458.被引 9
  • Effects of hypertension on the outcomes of COVID-19: a multicentre retrospective cohort study
    Zhong, Li; Wu, Yuting; Gao, Jinghua; Zhang, Jinxia; Xie, Qifeng; He, Huang; Ji, Jingjing; Liu, Zheying; Wang, Conglin; Liu, Zhifeng*Annals of Medicine, 2021, 53(1): 770-776.被引 10
查看全部 →

发表信息

论文状态
公开发表
期刊
Postgraduate Medical Journal
发表日期
2022-07
卷期
第 98 卷, 第 1161 期
页码
515-522
DOI
10.1136/postgradmedj-2021-140674
语言
ENGLISH
期刊等级
4区
成果收录
SCIE
资助标注
National Key Research and Development Plan of China [2020YFA0708001, 2020YFC0845300, 2020YFC0841600]; Guangdong Province Science and Technology Planning Project [2019A070717007]; Guangdong Provincial Department of Education Project [2020KZDZX1054]; Guangzhou University of Chinese Medicine [2021XK06, 2021XK49, 2021YJZX012]; Guangdong Provincial Bureau of Chinese Medicine [20191377]; Guangdong Provincial Hospital of Chinese Medicine fund [YN2019ML11, YN2019QJ13]

作者

  • C

    Chen, Jiankun (第一作者)

    2 · guangdong prov hosp · guangzhou univ chinese med

  • L

    Liu, Yuntao

    2 · guangdong prov hosp · guangzhou univ chinese med

查看全部 10 位作者收起作者
  • Q

    Qin, Jinying

    2 · guangdong prov hosp · guangzhou univ chinese med

  • R

    Ruan, Chunyan

    2 · guangdong prov hosp · guangzhou univ chinese med

  • Z

    Zeng, Xianghui

    2 · guangdong prov hosp · guangzhou univ chinese med

  • X

    Xu, Aiting

  • Y

    Yang, Rongyuan (通讯)

    2 · guangdong prov hosp · guangzhou univ chinese med

  • L

    Li, Jiqiang (通讯)

    2 · guangdong prov hosp · guangzhou univ chinese med

  • C

    Cai, Huayang (通讯)

    2 · guangdong prov hosp · guangzhou univ chinese med

  • Z

    Zhang, Zhongde

    2 · guangdong prov hosp · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417